MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. Common Stock (MBX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · MBX · as of Jun 8, 2026
Activity summary
Buy transactions
4
P-Purchase only
Sell transactions
4
12 Months
Buy/Sell ratio
1.00
Buy/Sell (by trades)
Overall sentiment
MBX Biosciences, Inc. Common Stock insiders have shown mixed buying and selling activity over the past 12 Months.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
MBX insider buying and selling by quarter
MBX insider selling · MBX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · MBX ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
MBX executive sell shares · MBX board member insider trading · MBX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 8, 2026 | Azoulay Salomon Chief Medical Officer | Option | 55,000 | $575K | Form 4 |
| May 8, 2026 | Azoulay Salomon Chief Medical Officer | Option | 15,003 | $240K | Form 4 |
| May 8, 2026 | Azoulay Salomon Chief Medical Officer | Sale | 15,003 | $575K | Form 4 |
| May 8, 2026 | Azoulay Salomon Chief Medical Officer | Sale | 55,000 | $2.11M⚡ | Form 4 |
| May 6, 2026 | Azoulay Salomon Chief Medical Officer | Sale | 231 | $7K | Form 4 |
| May 6, 2026 | Hawryluk P. Kent President & CEO · Director | Sale | 607 | $18K | Form 4 |
| May 1, 2026 | Hoerter Steven L. Director | Award | 11,938 | — | Form 4 |
| Mar 13, 2026 | Hawryluk P. Kent President & CEO · Director | Purchase | 18,500 | $526K | Form 4 |
| Feb 26, 2026 | Hawryluk P. Kent President & CEO · Director | Option | 28,768 | $460K | Form 4 |
| Feb 2, 2026 | Azoulay Salomon Chief Medical Officer | Award | 15,000 | — | Form 4 |
| Feb 2, 2026 | Bartram Richard CFO | Award | 15,000 | — | Form 4 |
| Feb 2, 2026 | Hawryluk P. Kent President & CEO · Director | Award | 35,250 | — | Form 4 |
| Oct 24, 2025 | Hawryluk P. Kent President & CEO · Director | Option | 182,859 | $594K | Form 4 |
| Oct 20, 2025 | Hawryluk P. Kent President & CEO · Director | Purchase | 20,000 | $273K | Form 4 |
| Oct 17, 2025 | Hoerter Steven L. Director | Purchase | 20,000 | $265K | Form 4 |
| Sep 26, 2025 | Heron Patrick J Director | Purchase | 666,666 | $12.00M⚡ | Form 4 |
| Apr 8, 2025 | Pescovitz Ora H. Director | Purchase | 7,693 | $45K | Form 4 |
Azoulay Salomon
Chief Medical Officer
Date
May 8
Shares
55,000
Price
$10.46
Value
$575K
Azoulay Salomon
Chief Medical Officer
Date
May 8
Shares
15,003
Price
$16.00
Value
$240K
Azoulay Salomon
Chief Medical Officer
Date
May 8
Shares
15,003
Price
$38.30
Value
$575K
Azoulay Salomon
Chief Medical Officer
Date
May 8
Shares
55,000
Price
$38.38
Value
$2.11M ⚡
Hawryluk P. Kent
President & CEO · Director
Date
May 6
Shares
607
Price
$29.54
Value
$18K
Hawryluk P. Kent
President & CEO · Director
Date
Mar 13
Shares
18,500
Price
$28.41
Value
$526K
Hawryluk P. Kent
President & CEO · Director
Date
Feb 26
Shares
28,768
Price
$16.00
Value
$460K
Hawryluk P. Kent
President & CEO · Director
Date
Feb 2
Shares
35,250
Price
—
Value
—
Hawryluk P. Kent
President & CEO · Director
Date
Oct 24
Shares
182,859
Price
$3.25
Value
$594K
Hawryluk P. Kent
President & CEO · Director
Date
Oct 20
Shares
20,000
Price
$13.64
Value
$273K
Heron Patrick J
Director
Date
Sep 26
Shares
666,666
Price
$18.00
Value
$12.00M ⚡
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About MBX insider trading
MBX insider trades
MBX Biosciences, Inc. Common Stock (MBX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Azoulay Salomon (Chief Medical Officer), Hawryluk P. Kent (President & CEO · Director), Hoerter Steven L. (Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. MBX insiders have been mixed buying and selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For MBX Biosciences, Inc. Common Stock's institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
MBX insider trading · 5 questionsThe insiders of MBX Biosciences, Inc. Common Stock (MBX) include executives and directors such as Azoulay Salomon (Chief Medical Officer), Hawryluk P. Kent (President & CEO · Director), Hoerter Steven L. (Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026